Early findings of prospective anti-HLA donor specific antibodies monitoring study in pancreas transplantation: Indiana University Health Experience

Clinical Transplantation

Volumn 26, Issue 5, 2012, Pages

  Mujtaba, Muhammad A ^a   Fridell, Jonathan A ^a   Higgins, Nancy ^a   Sharfuddin, Asif A ^a   Yaqub, Muhammad S ^a   Kandula, Praveen ^a   Chen, Jeanne ^a   Mishler, Dennis P ^a   Lobashevsky, Andrew ^a   Book, Benita ^a   Powelson, John ^a   Taber, Tim E ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody mediated rejection; Donor specific antibodies; Pancreas survival; Pancreas transplant

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBODY; COTRIMOXAZOLE; DONOR SPECIFIC ANTIBODY; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; VALGANCICLOVIR;

ADULT; ARTICLE; CYTOMEGALOVIRUS INFECTION; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT REJECTION; HLA SYSTEM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY PANCREAS TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PANCREAS TRANSPLANTATION; PNEUMOCYSTIS PNEUMONIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROPHYLAXIS; UNITED STATES;

ANIMALS; ANTILYMPHOCYTE SERUM; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HLA ANTIGENS; HUMANS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MONITORING, IMMUNOLOGIC; PANCREAS TRANSPLANTATION; PROSPECTIVE STUDIES; RABBITS; REMISSION INDUCTION;

EID: 84867629389     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12005     Document Type: Article

References (35)

1. Cantarovich D, Vistoli F. Minimization protocols in pancreas transplantation. Transpl Int 2009: 22: 61.
2. Drognitz O, Benz S, Pfeffer F et al. Long-term follow-up of 78 simultaneous pancreas-kidney transplants at a single-center institution in Europe. Transplantation 2004: 78: 1802.
3. Gruessner AC, Sutherland DE. Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of June 2004. Clin Transplant 2005: 19: 433.
4. Gruessner AC, Sutherland DE, Gruessner RW. Pancreas transplantation in the United States: a review. Curr Opin Organ Transplant 2010: 15: 93.
5. Waki K, Terasaki PI, Kadowaki T. Long-term pancreas allograft survival in simultaneous pancreas-kidney transplantation by era: UNOS registry analysis. Diabetes Care 2010: 33: 1789.
6. Humar A, Khwaja K, Ramcharan T et al. Chronic rejection: the next major challenge for pancreas transplant recipients. Transplantation 2003: 76: 918.
7. de Kort H, Munivenkatappa RB, Berger SP et al. Pancreas allograft biopsies with positive C4d staining and anti-donor antibodies related to worse outcome for patients. Am J Transplant 2010: 10: 1660.
8. Melcher ML, Olson JL, Baxter-Lowe LA, Stock PG, Posselt AM. Antibody-mediated rejection of a pancreas allograft. Am J Transplant 2006: 6: 423.
9. Munivenkatappa RB, Philosophe B, Papadimitriou JC, Drachenberg CB. Interacinar C4d staining in pancreas allografts. Transplantation 2009: 88: 145.
10. Pascual J, Samaniego MD, Torrealba JR et al. Antibody-mediated rejection of the kidney after simultaneous pancreas-kidney transplantation. J Am Soc Nephrol 2008: 19: 812.
11. Rangel EB, Malheiros DM, de Castro MC et al. Antibody-mediated rejection (AMR) after pancreas and pancreas-kidney transplantation. Transpl Int 2010: 23: 602.
12. Torrealba JR, Samaniego M, Pascual J et al. C4d-positive interacinar capillaries correlates with donor-specific antibody-mediated rejection in pancreas allografts. Transplantation 2008: 86: 1849.
13. Drachenberg CB, Torrealba JR, Nankivell BJ et al. Guidelines for the diagnosis of antibody-mediated rejection in pancreas allografts-updated Banff grading schema. Am J Transplant 2011: 11: 1792.
14. Everly MJ, Rebellato LM, Ozawa M et al. Beyond histology: lowering human leukocyte antigen antibody to improve renal allograft survival in acute rejection. Transplantation 2010: 89: 962.
15. Mujtaba MA, Goggins W, Lobashevsky A et al. The strength of donor-specific antibody is a more reliable predictor of antibody-mediated rejection than flow cytometry crossmatch analysis in desensitized kidney recipients. Clin Transplant 2011: 25: E96.
16. Terasaki PI. The review by Kwun and Knechtle-"can it B?"-asks whether B cells are responsible for chronic rejection of transplants. Transplantation 2009: 88: 978.
17. Lefaucheur C, Loupy A, Hill GS et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010: 21: 1398.
18. Einecke G, Sis B, Reeve J et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009: 9: 2520.
19. Papadimitriou JC, Drachenberg CB, Munivenkatappa R et al. Glomerular inflammation in renal allografts biopsies after the first year: cell types and relationship with antibody-mediated rejection and graft outcome. Transplantation 2010: 90: 1478.
20. Gaston RS, Cecka JM, Kasiske BL et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010: 90: 68.
21. Fridell JA, Mangus RS, Powelson JA. Histidine-tryptophan-ketoglutarate for pancreas allograft preservation: the Indiana University experience. Am J Transplant 2010: 10: 1284.
22. Fridell JA, Shah A, Milgrom ML, Goggins WC, Leapman SB, Pescovitz MD. Ipsilateral placement of simultaneous pancreas and kidney allografts. Transplantation 2004: 78: 1074.
23. Fridell JA, Milgrom ML, Henson S, Pescovitz MD. Use of the end-to-end anastomotic circular stapler for creation of the duodenoenterostomy for enteric drainage of the pancreas allograft [corrected]. J Am Coll Surg 2004: 198: 495.
24. Fridell JA, Mangus RS, Hollinger EF et al. The case for pancreas after kidney transplantation. Clin Transplant 2009: 23: 447.
25. Fridell JA, Agarwal A, Powelson JA et al. Steroid withdrawal for pancreas after kidney transplantation in recipients on maintenance prednisone immunosuppression. Transplantation 2006: 82: 389.
26. Gebel HM, Moussa O, Eckels DD, Bray RA. Donor-reactive HLA antibodies in renal allograft recipients: considerations, complications, and conundrums. Hum Immunol 2009: 70: 610.
27. Gloor J, Stegall MD. Sensitized renal transplant recipients: current protocols and future directions. Nat Rev Nephrol 2010: 6: 297.
28. Thielke JJ, West-Thielke PM, Herren HL et al. Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience. Transplantation 2009: 87: 268.
29. Bartlett ST, Drachenberg CB, Papadimitriou JC et al. Pancreas transplantation: the histologic morphology of graft loss and clinical correlations. Transplantation 2001: 71: 1784.
30. Zachary AA, Leffell MS. Detecting and monitoring human leukocyte antigen-specific antibodies. Hum Immunol 2008: 69: 591.
31. Zachary AA, Sholander JT, Houp JA, Leffell MS. Using real data for a virtual crossmatch. Hum Immunol 2009: 70: 574.
32. Cantarovich D, De Amicis S, Akl A et al. Posttransplant donor-specific anti-HLA antibodies negatively impact pancreas transplantation outcome. Am J Transplant 2011: 11: 2737.
33. Glotz D, Lefaucheur C, Suberbielle-Boissel C et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Contrib Nephrol 2009: 162: 1.
34. Mujtaba MA, Taber TE, Goggins WC et al. Early steroid withdrawal in repeat kidney transplantation. Clin J Am Soc Nephrol 2011: 6: 404.
35. Sutherland DE, Gruessner RW, Dunn DL et al. Lessons learned from more than 1, 000 pancreas transplants at a single institution. Ann Surg 2001: 233: 463.